Insider Transactions in Q1 2022 at Vir Biotechnology, Inc. (VIR)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 30
2022
|
Ann M. Hanly EVP & Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,627
-3.12%
|
$68,302
$26.24 P/Share
|
|
Mar 10
2022
|
George A Scangos Director |
BUY
Grant, award, or other acquisition
|
Direct |
111,000
+33.14%
|
-
|
|
Mar 10
2022
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+4.65%
|
$9,000
$1.53 P/Share
|
|
Mar 02
2022
|
Johanna Friedl Naderer EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+50.0%
|
-
|
|
Feb 22
2022
|
Howard Horn CFO |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+12.94%
|
-
|
|
Feb 22
2022
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-0.78%
|
$41,250
$30.0 P/Share
|
|
Feb 22
2022
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+0.77%
|
$1,375
$1.53 P/Share
|
|
Feb 22
2022
|
Herbert Virgin EVP, Research & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+28.52%
|
-
|
|
Feb 22
2022
|
Steven J. Rice Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+34.1%
|
-
|
|
Feb 22
2022
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,000
+29.94%
|
-
|
|
Feb 22
2022
|
Ann M. Hanly EVP & Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,500
+38.88%
|
-
|
|
Feb 18
2022
|
George A Scangos Director |
SELL
Open market or private sale
|
Direct |
17,726
-13.56%
|
$531,780
$30.65 P/Share
|
|
Feb 17
2022
|
Howard Horn CFO |
SELL
Open market or private sale
|
Direct |
2,393
-1.18%
|
$74,183
$31.93 P/Share
|
|
Feb 17
2022
|
Steven J. Rice Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
1,942
-9.43%
|
$60,202
$31.93 P/Share
|
|
Feb 17
2022
|
George A Scangos Director |
SELL
Open market or private sale
|
Direct |
10,024
-7.12%
|
$310,744
$31.93 P/Share
|
|
Feb 17
2022
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,293
-2.13%
|
$71,083
$31.93 P/Share
|
|
Feb 17
2022
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,009
-3.24%
|
$93,279
$31.93 P/Share
|
|
Feb 16
2022
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-5.11%
|
$155,000
$31.54 P/Share
|
|
Feb 16
2022
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.86%
|
$5,000
$1.53 P/Share
|
|
Feb 08
2022
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$45,375
$33.94 P/Share
|
|
Feb 08
2022
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Feb 02
2022
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-5.11%
|
$170,000
$34.52 P/Share
|
|
Feb 02
2022
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.86%
|
$5,000
$1.53 P/Share
|
|
Jan 25
2022
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$44,000
$32.46 P/Share
|
|
Jan 25
2022
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Jan 19
2022
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.59%
|
$175,000
$35.06 P/Share
|
|
Jan 19
2022
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.86%
|
$5,000
$1.53 P/Share
|
|
Jan 18
2022
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,173
-0.98%
|
$561,401
$37.39 P/Share
|
|
Jan 11
2022
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$48,125
$35.1 P/Share
|
|
Jan 11
2022
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Jan 05
2022
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.57%
|
$185,000
$37.46 P/Share
|
|
Jan 05
2022
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.86%
|
$5,000
$1.53 P/Share
|